Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 72804 record(s)

Req # A-2023-001388

Adverse Drug Reactions (ADRs). Report numbers: E2B_06758608, 001000647, E2B_06725619, E2B_06920034, E2B_06745245, E2B_06758044, E2B_02793560, E2B_06729415, 001071531, 001070296.

Organization: Health Canada

2954 page(s)
May 2024

Req # A-2023-001390

Adverse Drug Reactions (ADRs). Report numbers: 001059820, 001051355, 001043994, 001061093, E2B_06568436, E2B_05058863.

Organization: Health Canada

248 page(s)
May 2024

Req # A-2023-001426

Adverse Drug Reactions (ADRs) for Methotrexate. Report numbers: 001047194, 1046068. ADR for ASAPHEN. Report number: 001051189. ADR for Abiraterone acetate. Report number: E2B_06680076. ADR for Azithromycin. Report number: E2B_06624689. ADR for…

Organization: Health Canada

227 page(s)
May 2024

Req # A-2023-001428

Adverse Drug Reactions (ADRs). Report numbers: E2B_06809401, E2B_06773618.

Organization: Health Canada

26 page(s)
May 2024

Req # A-2023-001495

Adverse Drug Reactions (ADRs) for Entyvio. Report numbers: E2B_06833275, E2B_06803441, E2B_06770551, E2B_06831307, E2B_06796068, E2B_06807381. ADRs for Vedolizumab. Report numbers: E2B_06804360, E2B_06803544.

Organization: Health Canada

1244 page(s)
May 2024

Req # A-2023-001496

Adverse Drug Reactions (ADRs) for Mesalazine. Report numbers: E2B_06771537, E2B_06833186, E2B_06833149,E2B_06812382, E2B_06812379, E2B_06833251, E2B_06823606, E2B_06803318. ADR for Pantoloc. Report number: 001067920.

Organization: Health Canada

99 page(s)
May 2024

Req # A-2023-001501

Adverse Drug Reactions (ADRs). Report numbers: E2B_03872373, 001071948, 001069783.

Organization: Health Canada

26 page(s)
May 2024

Req # A-2023-001517

Adverse Drug Reactions (ADRs). Report numbers: E2B_05722719, E2B_05431322, 001008866, E2B_05700268, E2B_05775676, E2B_05740647, E2B_05932577, E2B_05794671, E2B_05950522, E2B_05794672.

Organization: Health Canada

124 page(s)
May 2024

Req # A-2023-001518

Adverse Drug Reactions (ADRs). Report numbers: E2B_06416488, E2B_05982904, 000995799, 000995417, E2B_06481181, 001051134, E2B_02566868 001013224, E2B_00685447, 001010349.

Organization: Health Canada

1805 page(s)
May 2024

Req # A-2023-001548

Adverse Drug Reactions (ADRs). Report numbers: E2B_06756603, 001070018.

Organization: Health Canada

12 page(s)
May 2024
Date modified: